IRIS
MARTINI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 49.916
AS - Asia 4.431
NA - Nord America 1.704
SA - Sud America 333
AF - Africa 82
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 2
Totale 56.476
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 49.075
SG - Singapore 2.121
US - Stati Uniti d'America 1.618
CN - Cina 1.108
VN - Vietnam 723
FR - Francia 431
BR - Brasile 207
HK - Hong Kong 142
FI - Finlandia 92
DE - Germania 82
CH - Svizzera 71
MX - Messico 53
AR - Argentina 50
GB - Regno Unito 48
JP - Giappone 48
BD - Bangladesh 41
IN - India 40
IQ - Iraq 29
ZA - Sudafrica 29
NL - Olanda 22
EC - Ecuador 21
ID - Indonesia 20
RU - Federazione Russa 19
PH - Filippine 18
CA - Canada 16
TR - Turchia 15
TH - Thailandia 14
CO - Colombia 13
PK - Pakistan 13
VE - Venezuela 13
CL - Cile 12
DZ - Algeria 12
IE - Irlanda 11
JO - Giordania 11
KR - Corea 11
KE - Kenya 9
MA - Marocco 9
PY - Paraguay 9
TW - Taiwan 9
NP - Nepal 8
SE - Svezia 8
AT - Austria 7
PL - Polonia 7
SA - Arabia Saudita 7
UA - Ucraina 7
EG - Egitto 6
ES - Italia 6
KZ - Kazakistan 6
RO - Romania 6
AU - Australia 5
BY - Bielorussia 5
AZ - Azerbaigian 4
CR - Costa Rica 4
LT - Lituania 4
MY - Malesia 4
OM - Oman 4
PE - Perù 4
QA - Qatar 4
SY - Repubblica araba siriana 4
UZ - Uzbekistan 4
GT - Guatemala 3
HR - Croazia 3
IL - Israele 3
LB - Libano 3
MM - Myanmar 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AM - Armenia 2
CY - Cipro 2
DO - Repubblica Dominicana 2
GA - Gabon 2
GM - Gambi 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
PA - Panama 2
PS - Palestinian Territory 2
RS - Serbia 2
SN - Senegal 2
TN - Tunisia 2
AD - Andorra 1
BE - Belgio 1
BO - Bolivia 1
BW - Botswana 1
BZ - Belize 1
CD - Congo 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
ET - Etiopia 1
HN - Honduras 1
IR - Iran 1
JM - Giamaica 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
LK - Sri Lanka 1
MD - Moldavia 1
ME - Montenegro 1
MQ - Martinica 1
MU - Mauritius 1
Totale 56.465
Salva come PNG Salva come JPEG
Città #
Genova 32.785
Genoa 9.437
Rapallo 4.079
Vado Ligure 2.570
Singapore 1.011
San Jose 675
Lauterbourg 412
Ashburn 393
Ho Chi Minh City 204
Hanoi 166
Hong Kong 134
Beijing 129
New York 98
Helsinki 88
Zurich 71
Bordighera 65
Santa Clara 62
Frankfurt am Main 61
Council Bluffs 56
Tokyo 44
Haiphong 38
Mexico City 29
Da Nang 28
Tianjin 22
Amsterdam 19
Los Angeles 18
Orem 17
City of London 15
Milan 14
Baghdad 13
Nuremberg 13
São Paulo 13
Cardiff 11
Chicago 11
Guangzhou 11
Johannesburg 11
Dublin 10
Hải Dương 10
Amman 9
Chennai 9
Denver 9
Atlanta 8
Biên Hòa 8
Guayaquil 8
Montreal 8
Phủ Lý 8
Rome 8
Thái Nguyên 8
Buffalo 7
Quito 7
Rio de Janeiro 7
Shanghai 7
Ankara 6
Bangkok 6
Can Tho 6
Cape Town 6
Des Moines 6
Long Xuyen 6
Nairobi 6
Naples 6
New Delhi 6
Santiago 6
Shenzhen 6
Berlin 5
Caxias do Sul 5
Charlotte 5
Hưng Yên 5
Jakarta 5
Ninh Bình 5
Paris 5
Pasadena 5
Phoenix 5
Poplar 5
Porto Alegre 5
Warsaw 5
Almaty 4
Baku 4
Dallas 4
Delhi 4
Doha 4
Houston 4
Lahore 4
Muscat 4
New Taipei City 4
Riyadh 4
Sydney 4
Tashkent 4
Toronto 4
Valenza 4
Vĩnh Long 4
Zapopan 4
Asunción 3
Bari 3
Belém 3
Boardman 3
Bogotá 3
Bologna 3
Buenos Aires 3
Bắc Ninh 3
Caracas 3
Totale 53.171
Salva come PNG Salva come JPEG
Nome #
Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. 269
Novel automated system for Magnetic Resonance Imaging quantification of the inflamed synovial membrane volume in patients with juvenile idiopathic arthritis. 252
CD70 deficiency due to a novel mutation in a patient with severe chronic EBV infection presenting as a periodic fever 239
A longitudinal printo study on growth and puberty in juvenile systemic lupus erythematosus. 233
ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study 229
A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis 212
Malattia di Menetrier e gastropatia ipertrofica proteino-disperdente transitoria del bambino: due entità cliniche distinte? 211
HRCT and pulmonary function tests in monitoring of lung involvement in juvenile systemic sclerosis. 204
Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 202
Delineating the application of ultrasound in detecting synovial abnormalities of subtalar joint in juvenile idiopathic arthritis 202
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 199
MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis. 198
Parent and child acceptable symptom state in juvenile idiopathic arthritis. 195
Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference 195
Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: Clinical and therapeutic implications 195
2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative 195
Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome 191
Candidate Genes in Patients with Autoinflammatory Syndrome Resembling Tumor Necrosis Factor Receptor-associated Periodic Syndrome Without Mutations in the TNFRSF1A Gene 190
A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. 189

Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Assessment of Disease Activity in Patients with Juvenile Idiopathic Arthritis 189
Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology 187
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects 186
HLA-DRB1∗11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis 186
Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. 184
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. 181
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis 181
The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 181
Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis 181
Differentiating PFAPA syndrome from monogenic periodic fevers. 180
Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study. 180
Agreement among musculoskeletal pediatric specialists in the assessment of radiographic joint damage in juvenile idiopathic arthritis. 180
Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study 179
A positive family history of psoriasis does not affect the clinical expression and course of juvenile idiopathic arthritis patients with oligoarthritis. 178
Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial 177
A circulating reservoir of pathogenic-like CD4+ T cells shares a genetic and phenotypic signature with the inflamed synovial micro-environment 177
Discordance between proxy-reported and observed assessment of functional ability of children with juvenile idiopathic arthritis. 175
The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 175
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. 172
A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report 172
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features 171
Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 171
Advances in biomarkers for paediatric rheumatic diseases 171
Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. 170
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept 170
Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis 168
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 167
Agreement between physicians and parents in rating functional ability of children with juvenile idiopathic arthritis. 165
Next-generation sequencing and its initial applications for molecular diagnosis of systemic auto-inflammatory diseases 165
The role of imaging in juvenile idiopathic arthritis 165
Cryopyrin-associated periodic syndromes in Italian Patients: Evaluation of the rate of somatic NLRP3 mosaicism and phenotypic characterization 164
The EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis, and childhood Takayasu arteritis: ankara 2008. part ii: final classification criteria. 163
Preliminary definition of improvement in juvenile arthritis. 163
Phenotypic and functional characterisation of CCR7+ and CCR7- CD4+ memory T cells homing to the joints in juvenile idiopathic arthritis. 163
Aortic valve regurgitation as the presenting sign of Takayasu arteritis. 163
Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis 162
Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. 162
Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis. 162
Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care 162
Antiphospholipid antibody syndrome in pediatric patients. 161
Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis 161
EULAR-PReS points to consider for the use of imaging in the diagnosis and management of juvenile idiopathic arthritis in clinical practice 161
Neurological disorders, other than stroke, associated with antiphospholipid antibodies in childhood. 161
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis 161
Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. 160
Hypocomplementemic urticarial vasculitis syndrome with severe systemic manifestations 160
Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. 159
Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. 159
Prevalence of anticardiolipin antibodies in juvenile chronic arthritis. 159
Development and initial validation of composite parent and child centered disease assessment indices for juvenile idiopathic arthritis. 159
Antinuclear antibody positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. 158
Development and validation of a composite disease activity score for juvenile idiopathic arthritis 157
Paediatric-onset systemic lupus erythematosus. 157
Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. 157
A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry 157
A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children 156
Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: A randomised trial 156
Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients 156
A randomized, double-blind, placebo-controlled trial of paracetamol and ketoprofren lysine salt for pain control in children with pharyngotonsillitis cared by family pediatricians 156
Criteria to define response to therapy in paediatric rheumatic diseases. 155
Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study. 155
An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis 154
Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis. 154
The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. 154
High prevalence of antiphospholipid antibodies in children with idiopatic cerebral ischemia 153
Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis 153
Marked and sustained improvement 2 years after autologous stem cell transplantation in a girl with systemic sclerosis. 153
Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. 152
In vivo neutralization of human IL-6 (hIL-6) achieved by immunization of hIL-6 transgenic mice with a hIL-6 receptor antagonist 152
A new short and simple health-related quality of life measure for paediatric rheumatic diseases: initial validation in juvenile idiopathic arthritis 152
Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. 152
Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study. 152
Adapted versions of the Sharp-van Der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis 151
Chronic recurrent multifocal osteomyelitis with unusual features. 151
The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. 151
Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy 151
Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries 151
Tolerance and auto-immunity: 50 years after burnet. 150
Phenotypic and functional characterization of switch memory B cells from patients with oligoarticular juvenile idiopathic arthritis 150
Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. 150
Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. 150
Totale 17.265
Salva come PNG Salva come JPEG
Categoria #
all - tutte 176.355
article - articoli 174.176
book - libri 0
conference - conferenze 296
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.883
Totale 352.710
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021870 0 0 0 0 0 0 0 0 0 364 221 285
2021/20225.612 171 427 630 448 325 240 441 1.288 206 453 330 653
2022/20234.949 550 245 44 420 847 977 23 467 920 33 345 78
2023/20242.129 147 374 45 210 197 346 117 134 96 53 105 305
2024/20256.173 98 574 247 384 818 675 545 875 310 360 501 786
2025/202610.445 1.203 404 625 925 1.536 1.363 2.031 557 855 946 0 0
Totale 57.047